Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jerzy Gumulka Insider Profile
4 Followers
Jerzy Gumulka, Director at CNS Pharmaceuticals, holds 43.01K shares in CNS Pharmaceuticals (Ticker: CNSP). Most recently, Jerzy Gumulka Bought $33,333 shares of CNS Pharmaceuticals on Feb 06, 2024 for an estimated value of 10.00K.
Profitable Transactions
0 out of 3 Profitable Transactions
Average Return
-93.60%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Jerzy Gumulka holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Apr 21, 2023 - Apr 21, 2024
Return:-89.30%
The most profitable trade made by Jerzy Gumulka
Jerzy Gumulka's Trading History
List of latest transactions for each holding click on a transaction to see Jerzy Gumulka's performance on stock
You May Also Like
Jerzy Gumulka insider profile FAQ
What is the percentage of profitable transactions made by Jerzy Gumulka?
The percentage of profitable transactions made by Jerzy Gumulka is 0%.
What is the average return per transaction made by Jerzy Gumulka?
The average return per transaction made by Jerzy Gumulka is -93.60%.
What stocks does Jerzy Gumulka hold?
Jerzy Gumulka holds: CNSP stocks.
What was Jerzy Gumulka’s latest transaction?
Jerzy Gumulka latest transaction was an Informative Buy of $10.00K.
What was Jerzy Gumulka's most profitable transaction?
Jerzy Gumulka’s most profitable transaction was an Informative Buy of CNSP stock on April 21, 2023. The return on the trade was -89.30%.
What is Jerzy Gumulka's role in CNS Pharmaceuticals?
Jerzy Gumulka's role in CNS Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.